Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Stock data | 2024 | Change |
---|---|---|
Price | $0.0001 | N/A |
Market Cap | $722.09 | N/A |
Shares Outstanding | 7.22M | N/A |
Employees | 2.00 | N/A |